Our team is highly experienced in the development and use of dynamic contrast-enhanced MRI (DCE-MRI), with decades of knowledge and numerous publications. We have defined many of the standard approaches to the technique’s implementation in clinical trials. DCE-MRI is widely used in oncology to help our clients assess the change in tumour vascular status in response to antiangiogenic and vascular disrupting therapies. Increasingly it is being used to assess inflammatory conditions such as rheumatoid arthritis, in studies of blood-brain barrier disruption and in the assessment of perfusion and vascular abnormalities in the lung.
DCE-MRI involves the use of standard clinical intravenously-administered gadolinium-based contrast agents. The delivery of the agent to the organ or tissue of interest is monitored over time using rapid volumetric imaging, and the concentration of the agent in the tissue and in the blood is quantified. The uptake and washout of the agent is interpreted using physiological modelling methods to provide imaging biomarkers of microvascular function.
DCE-MRI in the lung
DCE-MRI provides information on lung perfusion and other microvascular function, including capillary permability and leakage space. Application areas include pulmonary embolism, asthma, pulmonary hypertension and COPD. Bioxydyn provides clinical trial services for the use of DCE-MRI in these settings and also provides Pulmolux:dce to enable DCE-MRI research in the lung.
DCE-MRI in oncology
The Quantitative Imaging Biomarkers Alliance (QIBA) recognises the importance of DCE-MRI as a functional imaging biomarker of angiogenesis in cancer. Bioxydyn personnel bring decades of experience to the study of cancer using DCE-MRI within its clinical trial services capability.
DCE-MRI in inflammatory conditions
Bioxydyn provides expertise in the use of quantitative DCE-MRI for the assessment of inflammation. Particular areas of application include the use of DCE-MRI in the assessment of rheumatoid arthritis and in the assessment on lung inflammation. Bioxydyn's clinical trial services team work with centres worldwide in the use of DCE-MRI in this setting, and with Imorpics for the optimum analysis of DCE-MRI in arthritis.
DCE-MRI in neuroscience
DCE-MRI can be used to enable studies of blood-brain barrier (BBB) disruption, which typically require higher sensitivity to contrast agent uptake due to the lower levels of capillary permeability often observed in the brain. Bioxydyn clinical trial services personnel have years of experience of the use of DCE-MRI in this setting, including in the evaluation of BBB breakdown in stroke, neurodevelopmental conditions and neuro-oncology.